6 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Voir le projet
29
Participants partenaires
TERMINÉ
ANTIcipating the Global Onset of Novel Epidemics (ANTIGONE)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2016,
In recent years, an increased number of zoonotic viruses and bacteria have crossed the species barrier to humans and caused or threatened to cause human pandemics with high morbidity and mortality. Because of our inability to predict the emergence of these pathogens, it is difficult to take preventive measures. It is known that zoonotic pathogens need to cross barriers at the animal-human interfac ...
Voir le projet
14
Participants partenaires
TERMINÉ
New drugs targeting influenza virus polymerase (FLU-PHARM)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,
The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effective anti-influenza drug options when the public is not protected by vaccination. The need is pressing since several circulating strains are resistant to currently stock-piled anti-neuraminidase drugs. In this project, we will exploit our recent advances in t ...
Voir le projet
12
Participants partenaires
TERMINÉ
"Neutralizing antibodies against botulinum toxins A,B,E" (ANTIBOTABE)
Date du début: 1 sept. 2010, Date de fin: 28 févr. 2015,
"Botulinum neurotoxins (BoNTs), the most toxic substances known, are susceptible for use as bioweapons (listed as class A agents by CDC). Currently licensed animal derived antibodies or F(ab’)2 preparations, are at a high risk of inducing adverse effects and their privately-owned stockpiles are limited. In this project, we will target the most lethal types of BoNTs: A (subtypes A1 and A2), B (B1 a ...
Voir le projet
11
Participants partenaires
TERMINÉ
TOWARDS THE ESTABLISHMENT OF A FRAMEWORK IN MALARIA BETWEEN THE AMRN AND EVIMALAR (Ozmalnet)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,
54 partners from 34 institutes have formed an EC-funded Network of Excellence (NoE) in basic malaria research, the European Virtual Institute for Malaria Research (EVIMalaR). Over the previous >5 years as the NoE Biomalpar these partners successfully broke down many barriers to cooperation pursuing a programme of integrated research. This was greatly assisted by the Biomalpar PhD School whose stud ...
Voir le projet
14
Participants partenaires
TERMINÉ
The role of glycosphingolipids in development (GSL in development)
Date du début: 1 mars 2011, Date de fin: 30 sept. 2013,
Glycosphingolipids have been implicated in the development of various human pathologies, such as cancer, obesity, diabetes or Alzheimer diseases. Their wide implication in cellular membrane architecture and cellular signaling network and metabolism has however made difficult the establishment of an integrated and accurate understanding of their role in vivo. The current proposal aims to understand ...
Voir le projet